Clinical Trial Update: Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial exploring pegylated liposomal doxorubicin with a PD-1 inhibitor for muscle invasive bladder cancer is in progress, status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer

Drugs mentioned

• PD-1 inhibitor
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)

Snippet

Sponsor: Tianjin Medical University Second Hospital | Conditions: Muscle Invasive Bladder Cancer | Phase 2 | Status: UNKNOWN